Search
Ulotaront
go.drugbank.com/drugs/DB15665Investigational[A193506] SEP-363856 was developed by Sunovion pharmaceuticals. … Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5
Talsupram
go.drugbank.com/drugs/DB09191ExperimentalIt was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to [citalopram].
PBI-1402
go.drugbank.com/drugs/DB05480ExperimentalPBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.
XEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
Vitamin D
go.drugbank.com/drugs/DB11094ApprovedInvestigationalNutraceuticalVet approvedSince vitamin D can be endogenously synthesized in adequate amounts by most mammals exposed to sufficient quantities of sunlight, vitamin D functions like a hormone on vitamin D receptors to regulate calcium
Hyperforin
go.drugbank.com/drugs/DB01892InvestigationalNutraceuticalHyperforin is a phytochemical generated by the plants of the Hypericum family.
PW2101
go.drugbank.com/drugs/DB06483ExperimentalThe drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.
Sea salt
go.drugbank.com/drugs/DB11266ApprovedSea salt is a food ingredient and is often colored by adding charcoal or red clay to sometimes be referred to as “Hawaiian Sea Salt.”
Synonyms: bay saltGuselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalDeveloped by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Dordaviprone
go.drugbank.com/drugs/DB14844ApprovedInvestigationalOn August 6, 2025, dordaviprone was granted accelerated approval by the FDA.[L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation.